Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review
暂无分享,去创建一个
[1] Michel Wensing,et al. Economic barriers to implementation of innovations in health care: is the long run-short run efficiency discrepancy a paradox? , 2008, Health policy.
[2] E. Adang,et al. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions. , 2005, Health policy.
[3] Jerry Avorn,et al. Cost-Effectiveness of Genotype-Guided Warfarin Dosing for Patients With Atrial Fibrillation , 2009, Circulation. Cardiovascular quality and outcomes.
[4] Julie Ratcliffe,et al. Bridging the Gap: Exploring the Barriers to Using Economic Evidence in Healthcare Decision Making and Strategies for Improving Uptake , 2015, Applied Health Economics and Health Policy.
[5] Jean-Paul Moatti,et al. Cost-Effectiveness Analysis of Trastuzumab (Herceptin) in HER2-Overexpressed Metastatic Breast Cancer , 2009, American journal of clinical oncology.
[6] Karl Claxton,et al. The Value of Implementation and the Value of Information: Combined and Uneven Development , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.
[7] C. Sutton,et al. Developing and evaluating complex interventions. , 2014, Maternal & child nutrition.
[8] Katherine Payne,et al. Cost-effectiveness analyses of genetic and genomic diagnostic tests , 2018, Nature Reviews Genetics.
[9] L. Wilton,et al. The clinical effectiveness of preimplantation genetic diagnosis for aneuploidy in all 24 chromosomes (PGD-A): systematic review. , 2015, Human reproduction.
[10] M. Lux,et al. Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model , 2009, Breast Cancer Research and Treatment.
[11] P O Collinson,et al. Randomised Assessment of Treatment using Panel Assay of Cardiac markers--Contemporary Biomarker Evaluation (RATPAC CBE). , 2013, Health technology assessment.
[12] Mehdi Najafzadeh,et al. Barriers for integrating personalized medicine into clinical practice: A qualitative analysis , 2013, American journal of medical genetics. Part A.
[13] Carlos Crespo,et al. Genomic profile of breast cancer: cost–effectiveness analysis from the Spanish National Healthcare System perspective , 2014, Expert review of pharmacoeconomics & outcomes research.
[14] T. Delea,et al. Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor- and HER2-Positive Metastatic Breast Cancer , 2013, Breast Care.
[15] A F Monk,et al. ASSESSMENT OF THE LEARNING CURVE IN HEALTH TECHNOLOGIES , 2000, International Journal of Technology Assessment in Health Care.
[16] Paul Keown,et al. Cost‐Effectiveness of Organ Donation: Evaluating Investment into Donor Action and Other Donor Initiatives , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[17] Katherine Payne,et al. Removing barriers to a clinical pharmacogenetics service. , 2008, Personalized medicine.
[18] David Cameron,et al. Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab , 2012, The European Journal of Health Economics.
[19] Kenneth A. Freedberg,et al. Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial , 2012, AIDS.
[20] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.
[21] Murray Krahn,et al. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Michael Hauptmann,et al. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. , 2010, European journal of cancer.
[23] Niteesh Choudhry,et al. Cost‐effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer , 2013, Cancer.
[24] Scott D Ramsey,et al. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). , 2008, Lung cancer.
[25] A. Rademaker,et al. Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: A call for dialogue , 2009, Genetics in Medicine.
[26] Katherine Payne,et al. The economic case for precision medicine , 2018, Expert review of precision medicine and drug development.
[27] Antonis C. Antoniou,et al. Cost‐effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry , 2017, American journal of obstetrics and gynecology.
[28] M. Broder,et al. Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer. , 2011, The American journal of managed care.
[29] D. Petrie,et al. The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study , 2013, British Journal of Cancer.
[30] S. Chick,et al. A taxonomy of model structures for economic evaluation of health technologies. , 2006, Health economics.
[31] J. Hochman,et al. Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost‐effectiveness analysis , 2013, Journal of thrombosis and haemostasis : JTH.
[32] Katherine Payne,et al. The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[33] L. Mantovani,et al. KRAS Early Testing: Consensus Initiative and Cost-Effectiveness Evaluation for Metastatic Colorectal Patients in an Italian Setting , 2014, PloS one.
[34] Medical Advisory Secretariat. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. , 2010, Ontario health technology assessment series.
[35] C Proudlove,et al. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. , 2010, Health technology assessment.
[36] M Sculpher,et al. Evaluating the cost-effectiveness of interventions designed to increase the utilization of evidence-based guidelines. , 2000, Family practice.
[37] Willem H Woertman,et al. A model to correct for short-run inefficiencies in economic evaluations in healthcare. , 2012, Health economics.
[38] Bernhard Holzner,et al. Cost–utility analyses of drug therapies in breast cancer: a systematic review , 2016, Breast Cancer Research and Treatment.
[39] Trevor A Sheldon,et al. What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes, and interviews , 2004, BMJ : British Medical Journal.
[40] Louis P Garrison,et al. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[41] Milton C Weinstein,et al. Packaging Health Services When Resources Are Limited: The Example of a Cervical Cancer Screening Visit , 2006, PLoS medicine.
[42] E. Adang,et al. Economic evaluation of innovative technologies in health care should include a short-run perspective , 2008, The European Journal of Health Economics.
[43] Ariel Hammerman,et al. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[44] Matt Stevenson,et al. Methods for handling uncertainty within pharmaceutical funding decisions , 2014, Int. J. Syst. Sci..
[45] Bruce Wang,et al. Assessing the potential cost‐effectiveness of retesting IHC0, IHC1+, or FISH‐negative early stage breast cancer patients for HER2 status , 2013, Cancer.
[46] Eddy M. Adang,et al. Time to incorporate time in cost-effectiveness analysis , 2012, The European Journal of Health Economics.
[47] J. Bergh,et al. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[48] R Charles Coombes,et al. Stratified, precision or personalised medicine? Cancer services in the 'real world' of a London hospital. , 2017, Sociology of Health and Illness.
[49] Brent C Opmeer,et al. Diagnostic strategies for endometrial cancer in women with postmenopausal bleeding: cost-effectiveness of individualized strategies. , 2012, European journal of obstetrics, gynecology, and reproductive biology.
[50] David Moher,et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement , 2013, International Journal of Technology Assessment in Health Care.
[51] Surasak Saokaew,et al. Cost-Effectiveness Analysis of HLA-B*5801 Testing in Preventing Allopurinol-Induced SJS/TEN in Thai Population , 2014, PloS one.
[52] Jade K. Forwood,et al. Structural Characterization of a Gcn5-Related N-Acetyltransferase from Staphylococcus aureus , 2014, PloS one.
[53] Gert Jan van der Wilt,et al. UNDERSTANDING AND ANTICIPATING LAG-TIME BIAS IN COST-EFFECTIVENESS STUDIES: THE ROLE OF TIME IN COST-EFFECTIVENESS ANALYSIS , 2014, International Journal of Technology Assessment in Health Care.
[54] Stuart Peacock,et al. Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[55] Ron Goeree,et al. Capacity Constraints and Cost-Effectiveness: A Discrete Event Simulation for Drug-Eluting Stents , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.
[56] David W. Dowdy,et al. Clinical Effectiveness and Cost-Effectiveness of HIV Pre-Exposure Prophylaxis in Men Who Have Sex with Men: Risk Calculators for Real-World Decision-Making , 2014, PloS one.
[57] Julie Sakowski,et al. Economic Perspectives on Personalized Health Care and Prevention , 2013, Forum for health economics & policy.
[58] Alastair Fischer,et al. Health care resource allocation: is the threshold rule good enough? , 2004, Journal of health services research & policy.
[59] Valesca P Retèl,et al. Scenario drafting to anticipate future developments in technology assessment , 2012, BMC Research Notes.
[60] Gary H Lyman,et al. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. , 2005, The American journal of managed care.
[61] A. Hughes. Oxford English Dictionary. , 2008, Isis; an international review devoted to the history of science and its cultural influences.
[62] Tae-Jin Lee,et al. Cost-Effectiveness Analysis of Adjuvant Hormonal Treatments for Women with Postmenopausal Hormone-Receptor Positive Early Breast Cancer in the Korean Context , 2010 .
[63] W. Gradishar,et al. Barriers to the use of personalized medicine in breast cancer. , 2012, Journal of oncology practice.
[64] Karl Claxton,et al. Characterizing structural uncertainty in decision analytic models: a review and application of methods. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[65] Hiroshi Ishiguro,et al. Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan , 2008, Breast Cancer Research and Treatment.
[66] David Cutler,et al. Cost-Effectiveness of Multiplexed Predictive Biomarker Screening in Non-Small-Cell Lung Cancer , 2015 .
[67] J. Severens,et al. Value for money of changing healthcare services? Economic evaluation of quality improvement , 2003, Quality & safety in health care.
[68] John Hornberger,et al. US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer. , 2011, Journal of oncology practice.
[69] M. Villasís-Keever,et al. A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours , 2008, British Journal of Cancer.
[70] E. Pearson. Personalized medicine in diabetes: the role of ‘omics’ and biomarkers , 2016, Diabetic medicine : a journal of the British Diabetic Association.
[71] Gijs van de Wetering,et al. Quantifying short run cost-effectiveness during a gradual implementation process , 2013, The European Journal of Health Economics.
[72] Medical Advisory Secretariat. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis. , 2010, Ontario health technology assessment series.